U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07147361) titled 'Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma' on Aug. 14.
Brief Summary: This study is a multicenter cohort investigation integrating both retrospective and prospective components, designed to evaluate the predictive performance of combined blood ELISA testing and tissue multiplex immunofluorescence (mIF) staining for assessing treatment response to PD-1 inhibitors in patients with squamous cell carcinoma.
The retrospective cohort will analyze clinical data and pretreatment specimens (tissue biopsies and blood samples) from SCC patients who received PD-1 inhibitor therapy between April 2022 and June ...